U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H20FN7.C4H4O4
Molecular Weight 505.501
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ILGINATINIB MALEATE

SMILES

OC(=O)\C=C/C(O)=O.C[C@H](NC1=NC(NC2=NC=CN=C2)=CC(=C1)C3=CN(C)N=C3)C4=CC=C(F)C=C4

InChI

InChIKey=OVAGJAAQMBYZDS-FXSDFHGDSA-N
InChI=1S/C21H20FN7.C4H4O4/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21;5-3(6)1-2-4(7)8/h3-14H,1-2H3,(H2,24,26,27,28);1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C21H20FN7
Molecular Weight 389.4288
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

NS-018 is a potent inhibitor of Janus kinase 2 (JAK2) enzyme activity and Src-family kinases. It was developed as an oral therapy for the treatment of myelofibrosis. Overall NS-018 has been used in trials studying the treatment of primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia. NS-018 is a highly active JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). NS-018 also inhibits Src-family kinases, especially SRC and FYN, and weakly inhibits ABL and FLT3 with 45- and 90-fold selectivity for JAK2, respectively. NS-018 shows potent inhibitory activity against cell lines JAK2V617F or MPLW515L mutations or the TEL-JAK2 fusion gene.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.72 nM [IC50]
22.0 nM [IC50]
33.0 nM [IC50]
39.0 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.
2011 Jul
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.
2014 Jan 10
Patents

Sample Use Guides

In this phase I, dose-escalation portion of a phase I/II study, patients with myelofibrosis received oral NS-018 in continuous 28-day cycles. Once daily NS-018 at 300 mg was chosen as the phase II study dose based on improved tolerability compared with higher doses.
Route of Administration: Oral
NS-018 is a highly active JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). NS-018 shows potent inhibitory activity against cell lines JAK2V617F or MPLW515L mutations or the TEL-JAK2 fusion gene (expressing a constitutively activated JAK2) with IC50 of 11-120 nM, but has only minimal cytotoxicity against most other hematopoietic cell lines that have no constitutively activated JAK2.
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:12:30 UTC 2023
Edited
by admin
on Sat Dec 16 11:12:30 UTC 2023
Record UNII
8P0KTT2T1Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ILGINATINIB MALEATE
Common Name English
NS-018 MALEATE
Common Name English
N-[(1S)-1-(4- fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6-diamine maleate
Systematic Name English
2,6-PYRIDINEDIAMINE, N2-((1S)-1-(4-FLUOROPHENYL)ETHYL)-4-(1-METHYL-1H-PYRAZOL-4-YL)-N6-2-PYRAZINYL-, (2Z)-2-BUTENEDIOATE (1:1)
Systematic Name English
(S)-N-(1-(4-FLUOROPHENYL)ETHYL)-4-(1-METHYL-1H-PYRAZOL-4-YL)-N'-(PYRAZIN-2-YL)PYRIDINE-2,6-DIAMINE MALEATE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 916522
Created by admin on Sat Dec 16 11:12:30 UTC 2023 , Edited by admin on Sat Dec 16 11:12:30 UTC 2023
Code System Code Type Description
PUBCHEM
56599590
Created by admin on Sat Dec 16 11:12:30 UTC 2023 , Edited by admin on Sat Dec 16 11:12:30 UTC 2023
PRIMARY
CAS
1354799-87-3
Created by admin on Sat Dec 16 11:12:30 UTC 2023 , Edited by admin on Sat Dec 16 11:12:30 UTC 2023
PRIMARY
SMS_ID
100000183577
Created by admin on Sat Dec 16 11:12:30 UTC 2023 , Edited by admin on Sat Dec 16 11:12:30 UTC 2023
PRIMARY
FDA UNII
8P0KTT2T1Z
Created by admin on Sat Dec 16 11:12:30 UTC 2023 , Edited by admin on Sat Dec 16 11:12:30 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY